Q32 Bio Inc (QTTB)

NASDAQ
Currency in USD
1.390
+0.030(+2.21%)
Closed·
After Hours
1.490+0.100(+7.194%)
·
QTTB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Post-Market activity
Fair Value
Day's Range
1.3501.430
52 wk Range
1.34553.790
Key Statistics
Edit
Prev. Close
1.39
Open
1.38
Day's Range
1.35-1.43
52 wk Range
1.345-53.79
Volume
106.78K
Average Volume (3m)
147.71K
1-Year Change
-92.68%
Book Value / Share
-0.33
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
QTTB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.000
Upside
+763.31%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Q32 Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Neutral
Moving Averages
Strong Sell

Q32 Bio Company Profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.

Q32 Bio Inc SWOT Analysis


Pipeline Pivot
Explore Q32 Bio's strategic shift following setbacks in bempikibart trials, with focus now on ADX-097 as the key value driver for inflammatory disease treatments
Market Reaction
Delve into the dramatic stock price decline and market cap reduction, reflecting investor concerns about Q32 Bio's narrowed pipeline and future prospects
Financial Resilience
Learn about Q32 Bio's strong liquidity position, with a current ratio of 6.53, indicating ability to weather recent setbacks and fund ongoing research
Future Outlook
Analyst price targets range from $9 to $22, hinging on ADX-097's Phase 2 renal basket trial results expected in early 2025, potentially reshaping company valuation
Read full SWOT analysis

Compare QTTB to Peers and Sector

Metrics to compare
QTTB
Peers
Sector
Relationship
P/E Ratio
−0.3x−3.8x−0.5x
PEG Ratio
0.00−0.010.00
Price/Book
−4.2x1.6x2.6x
Price / LTM Sales
-15.9x3.1x
Upside (Analyst Target)
-181.4%47.8%
Fair Value Upside
Unlock12.1%6.9%Unlock

Analyst Ratings

1 Buy
2 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 12.000
(+763.31% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.90 / -0.80
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

QTTB Income Statement

FAQ

What Is the Q32 Bio (QTTB) Stock Price Today?

The Q32 Bio stock price today is 1.39.

What Stock Exchange Does Q32 Bio Trade On?

Q32 Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Q32 Bio?

The stock symbol for Q32 Bio is "QTTB."

What Is the Q32 Bio Market Cap?

As of today, Q32 Bio market cap is 16.95M.

What Is Q32 Bio's Earnings Per Share (TTM)?

The Q32 Bio EPS (TTM) is -4.93.

From a Technical Analysis Perspective, Is QTTB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Q32 Bio Stock Split?

Q32 Bio has split 1 times.

How Many Employees Does Q32 Bio Have?

Q32 Bio has 29 employees.

What is the current trading status of Q32 Bio (QTTB)?

As of 09 Jul 2025, Q32 Bio (QTTB) is trading at a price of 1.39, with a previous close of 1.39. The stock has fluctuated within a day range of 1.35 to 1.43, while its 52-week range spans from 1.35 to 53.79.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.